Department of Gastroenterology, Metabolic Diseases, Internal Medicine and Dietetics, Heliodor Swiecicki Clinical Hospital, Poznan University of Medical Sciences, Poznan, Poland.
JPEN J Parenter Enteral Nutr. 2021 Feb;45(2):430-433. doi: 10.1002/jpen.1875. Epub 2020 Jun 11.
Inflammatory bowel disease (IBD) patients with severe infections, abscess, or sepsis are ineligible for standard treatment using biological and immunosuppressive drug regimens. We report a case of complicated Crohn's disease with ruptured abdominal abscess, presence of enterocutaneous fistula, and sepsis. We also report and discuss patient management with parenteral nutrition (PN) and enteral nutrition (EN) and treatment outcomes. We report a case of a 31-year-old female with a 10-year history of IBD in clinical remission, who, after previous total proctocolectomy with J-pouch, presented to the clinic with severe abdominal pain of 2 days, unintentional weight loss, fatigue, fever, and abdominal abscess, which ruptured, and her clinical state became complicated by sepsis. PN was initiated using individually prepared admixture according to patient requirements, because of inability to tolerate any oral intake. Following the remittance of ileus symptoms, EN was added using a semielemental formula via a nasojejunal tube. Upon completion of the treatment, the fistula resolved, the wound had healed, and Crohn's Disease Activity Index score showed remission. This qualified the patient for initiation of biological therapy with infliximab. Patients with severe infections, abscesses, or sepsis are ineligible for standard IBD treatment using biological and immunosuppressive drug regimens. Furthermore, usually patients' nutrition condition prevents them from combating infection and initiating proper healing process. This case demonstrates the importance of considering nutrition therapy-PN and EN-in unstable patients who cannot be treated with standard pharmacological therapy. Nutrition therapy offers a bridge that allows patients to stabilize and heal before starting standard pharmacological treatment with immunosuppressive agents or biological therapy.
炎症性肠病(IBD)患者如果发生严重感染、脓肿或败血症,则不符合使用生物制剂和免疫抑制剂方案进行标准治疗的条件。我们报告了一例并发克罗恩病的复杂病例,该患者出现了腹部脓肿破裂、肠皮肤瘘和败血症。我们还报告并讨论了患者的肠外营养(PN)和肠内营养(EN)管理以及治疗结果。我们报告了一例 31 岁女性患者,她患有 IBD 病史 10 年,临床缓解,在先前接受全直肠结肠切除和 J 袋造口术后,因剧烈腹痛 2 天、非自愿性体重减轻、疲劳、发热和腹部脓肿就诊,脓肿破裂,其临床状态因败血症而复杂化。由于无法耐受任何口服摄入,因此根据患者需求使用单独配制的混合物开始进行 PN。在肠梗阻症状缓解后,通过鼻空肠管添加半要素配方的 EN。治疗完成后,瘘管得到解决,伤口愈合,克罗恩病活动指数评分显示缓解。这使患者有资格开始使用英夫利昔单抗进行生物治疗。发生严重感染、脓肿或败血症的患者不符合使用生物制剂和免疫抑制剂方案进行标准 IBD 治疗的条件。此外,通常情况下,患者的营养状况会阻止他们对抗感染并启动适当的愈合过程。该病例证明了对于不能接受标准药物治疗的不稳定患者,考虑营养治疗-肠外营养和肠内营养的重要性。营养治疗提供了一个桥梁,使患者在开始使用免疫抑制剂或生物治疗进行标准药物治疗之前能够稳定和愈合。